October 12, 2018 / 11:15 AM / a month ago

Bristol-Myers' Opdivo fails to meet lung cancer study goal

Oct 12 (Reuters) - Bristol-Myers Squibb Co said on Friday its blockbuster cancer drug Opdivo failed to meet the main goal in patients with a type of lung cancer, that had relapsed after chemotherapy.

The late-stage study was testing Opdivo against the current standard of care, chemotherapy, in patients suffering from small cell lung cancer, an aggressive form of the disease. (Reporting by Manas Mishra in Bengaluru; Editing by Shounak Dasgupta)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below